AstraZeneca logo

AstraZenecaNASDAQ: AZN

Profile

Sector:

Healthcare

Country:

United Kingdom

IPO:

12 May 1993

Next earnings report:

12 November 2024

Last dividends:

09 August 2024

Next dividends:

N/A
$226.34 B
-17%vs. 3y high
100%vs. sector
-92%vs. 3y high
57%vs. sector
-17%vs. 3y high
84%vs. sector
-23%vs. 3y high
58%vs. sector

Price

after hours | 9 min ago
$73.00+$1.99(+2.80%)
$12.94 B$13.09 B
$12.94 B$1.93 B

Analysts recommendations

Institutional Ownership

AZN Latest News

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
zacks.com01 November 2024 Sentiment: -

In the most recent trading session, Astrazeneca (AZN) closed at $71.42, indicating a +0.38% shift from the previous trading day.

AstraZeneca hit again as Chinese president investigated by police
proactiveinvestors.co.uk31 October 2024 Sentiment: NEGATIVE

AstraZeneca PLC (LSE:AZN) has confirmed that the president of its China division has been placed under investigation by local police as part of an anti-corruption drive. Leon Wang, who forms part of its senior executive team, is cooperating with an investigation by Chinese authorities said a statement yesterday from the pharma group released during the Budget speech without giving further details.

AstraZeneca says its China operations president under investigation
reuters.com30 October 2024 Sentiment: NEGATIVE

AstraZeneca said on Wednesday the company's China President Leon Wang is currently under investigation and is cooperating with Chinese authorities.

Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
zacks.com25 October 2024 Sentiment: NEUTRAL

Astrazeneca (AZN) closed the most recent trading day at $75.05, moving -1.12% from the previous trading session.

Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 Diabetes
globenewswire.com23 October 2024 Sentiment: POSITIVE

ECC5004/AZD5004 is an investigational oral small molecule GLP-1 receptor agonist licensed to AstraZeneca in November 2023 ECC5004/AZD5004 is an investigational oral small molecule GLP-1 receptor agonist licensed to AstraZeneca in November 2023

AstraZeneca Receives CHMP's Approval for Wainzua in Europe
zacks.com22 October 2024 Sentiment: POSITIVE

The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.

AZN or NVO: Which Is the Better Value Stock Right Now?
zacks.com14 October 2024 Sentiment: POSITIVE

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Astrazeneca (AZN) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?

Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com09 October 2024 Sentiment: POSITIVE

Astrazeneca (AZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
zacks.com08 October 2024 Sentiment: POSITIVE

AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.

AstraZeneca Collaborates with CSPC to Develop Innovative Lp(a) Inhibitor
gurufocus.com07 October 2024 Sentiment: POSITIVE

AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.

What type of business is AstraZeneca?

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

What sector is AstraZeneca in?

AstraZeneca is in the Healthcare sector

What industry is AstraZeneca in?

AstraZeneca is in the Drug Manufacturers - General industry

What country is AstraZeneca from?

AstraZeneca is headquartered in United Kingdom

When did AstraZeneca go public?

AstraZeneca initial public offering (IPO) was on 12 May 1993

What is AstraZeneca website?

https://www.astrazeneca.com

Is AstraZeneca in the S&P 500?

No, AstraZeneca is not included in the S&P 500 index

Is AstraZeneca in the NASDAQ 100?

Yes, AstraZeneca is included in the NASDAQ 100 index

Is AstraZeneca in the Dow Jones?

No, AstraZeneca is not included in the Dow Jones index

When was AstraZeneca the previous earnings report?

No data

When does AstraZeneca earnings report?

The next expected earnings date for AstraZeneca is 12 November 2024